What is the Current Role of Taxanes in the Treatment of Metastatic Prostate Cancer?

Since it FDA approval in 2004, docetaxel (a taxane based chemotherapy) has been the standard first-line chemotherapy for men with metastatic prostate cancer (mCRPC). Other than the trial of Provenge all the successful phase III trials conducted in mCRPC focused on men experiencing cancer progression after first-line docetaxel chemotherapy. The implication is that improving the [...]

No Difference In Ketoconazole Response For Men With Advanced Prostate Cancer Post Chemotherapy Failure

The use of Ketoconazole (Keto) in men with advanced prostate cancer is not considered mainstream, however there is clear evidence that it does reduce PSA in men with castrate resistant prostate cancer. Currently, most men with advanced prostate cancer who do use Keto utilize it prior to chemotherapy. There has been little literature evaluating the [...]

Carboplatin – A 2nd line chemotherapy?

Carboplatin is a chemotherapy agent used for treatment of many types of cancer. Currently, it is approved by the Food & Drug Administration (FDA) for treating patients with ovarian and non-small cell lung cancer. However, some oncologists use carboplatin “off-label” for other cancers. Commonly, these “off-label” uses include testicular, stomach, and bladder cancers as well [...]

Testaxel – A New Phase 2 Trial for Men Who Are Chemo Naive and Who Have Failed Chemotherapy

A new Phase 2 clinical trial of tesetaxel in men with castrate resistant advanced prostate cancer will be conducted through the Prostate Cancer Clinical Trials Consortium (PCCTC). Tesetaxel, an oral taxane which is in clinical development, will be evaluated for its use as both first- and second-line chemotherapy. […]

IxMP – A Potential Second or Third Line Chemotherapy- On The Horizon

Can IxMP Be Used as a Second or Third-Line Chemotherapy for Metastatic Castrate Resistant Prostate Cancer? There was a report recently released about a Phase 2 study from the Department of Defense funded Prostate Cancer Clinical Trials Consortium that suggests that ixabepilone + mitoxantrone + prednisone may have clinically significant activity as a form of [...]

Docetaxel (Chemotherapy) Re-Treatment – Can It Work Again?

A group of researchers from the Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Università Federico II, Napoli, Italy wanted to know if retreatment with docetaxel could be tolerated and have a positive effect in men with castration-resistant prostate cancer (CRPC) who have already failed chemotherapy. The researchers evaluated 45 men who had initially responded [...]

Sanofi-aventis Announces that Jevtana® (cabazitaxel) Injection Is Now Available in the U.S.

Sanofi-aventis, the pharmaceutical company that makes taxotere and the newly approved drug, Jevtana (cabazitaxel) yesterday announced that their newly approved treatment for men with metastatic hormone-refractory prostate cancer (mHRPC) who have been previously treated with a docetaxel-based treatment regimen and failed is finally available for distribution in the United States. Around one month ago, Jevtana [...]

A New Phase II Trial for Men with Androgen Independent Prostate Cancer After the Failure of Chemotherapy

Once we develop metastatic androgen-independent prostate cancer and experience disease progression after receiving docetaxel-based chemotherapy we have no approved treatment options. We have hit the proverbial wall! In the process of attempting to develop additional treatments, ImClone Systems Inc. (NASDAQ: IMCL), announced the beginning of a Phase II clinical trial for men with advanced prostate [...]